Publications by authors named "Felix A de la Iglesia"
Objectives: Analgesic synergy and improved tolerability have been reported for flexible dose morphine and oxycodone combinations. This report describes two studies with similar double-blind, randomized, 7-day crossover designs (up to 7 days per arm) conducted to 1) explore the analgesic and safety benefit offixed ratio of morphine (M) and oxycodone (0) combinations (MOX) and 2) define the optimal ratio for morphine and oxycodone combination.
Setting: Clinical study centers in Australia.
Article Synopsis
- Previous research identified Q8009, a protease from the venom of the Australian brown snake, known for its Factor Xa-like activity and ability to promote blood clotting.
- The current study evaluated Q8009's effectiveness in reducing blood loss and speeding up clotting in rats with injuries to the spleen, liver, and kidney, finding it significantly improved results compared to thrombin.
- Results showed that Q8009 significantly decreased total blood loss and time-to-hemostasis across all organ models, demonstrating its potential as a more effective hemostatic agent than traditional treatments.
Background And Aims: Neonatal necrotizing enterocolitis (NEC) is a common and serious acquired gastrointestinal tract condition. This clinical study assessed the potential clinical efficacy and microscopic effects of recombinant human epidermal growth factor 1-48 (EGF(1-48)) in neonates with NEC.
Methods: This prospective, double-blind, randomized controlled study included 8 neonates with NEC.
The antidiabetic agent troglitazone was given to groups of 4 cynomolgus monkeys per sex at 300, 600, or 1200 mg/kg daily by gavage for 52 weeks. A group of 4 monkeys per sex received vehicle alone and served as controls. Emesis and soft stool or diarrhea occurred sporadically in all troglitazone-treated groups, but did not compromise animal health.
View Article and Find Full Text PDFDyslipoproteinemias represent a group of disorders closely related to alterations of cholesterol and triglycerides. The alterations of these lipids are considered important risk factors in coronary heart disease and indicate the need for clinically effective and safe drugs. Hypolipidemic agent therapy, however, does not appear without risk since the administration of these agents is by necessity, on a long-term basis.
View Article and Find Full Text PDF